JayHTraverseMD
Cardiology • Minneapolis, MNInterventional Cardiology
Associate Professor, Medicine, University of Minnesota Medical School, Minneapolis
Dr. Traverse is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Minneapolis Heart Institute
920 East 28th Street, Suite 300
Minneapolis, MN 55407Phone+1 612-863-3900Fax+1 612-863-3784- Is this information wrong?
Summary
- Dr. Jay Traverse is a cardiologist in Minneapolis MN and is affiliated with multiple hospitals in the area, including Abbott Northwestern Hospital and New Ulm Medical Center. He received his medical degree from Case Western Reserve University School of Medicine and has been in practice 28 years. He specializes in interventional cardiology and is experienced in interventional cardiology, cardiac catheterization, and percutaneous coronary intervention.
Education & Training
University of MinnesotaFellowship, Cardiovascular Disease, 1992 - 1996- University of MinnesotaResidency, Internal Medicine, 1989 - 1992
Case Western Reserve University School of MedicineClass of 1989
University of Notre DameBS, Chemical Engineering- University of VirginiaME, Biomedical Engineering
Certifications & Licensure
MN State Medical License 1991 - 2024- American Board of Internal Medicine Interventional Cardiology
- National Board of Physicians and Surgeons Cardiovascular Disease
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Interventional Cardiology
Awards, Honors, & Recognition
- FAHA American Heart Assiciation
- FSCAI Society for Coronary Angiography and Interventions
- Vice Chairman of Cardiology Abbott Northwestern Hospital
- Join now to see all
Clinical Trials
- Bone Marrow Stem Cell Infusion Following a Heart Attack Start of enrollment: 2005 Dec 01
- Post-conditioning to Reduce Infarct Size Start of enrollment: 2008 Sep 01
- IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction Start of enrollment: 2012 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- The changing landscape of cardiac co-morbidities and in-hospital cardiac complications mediating Covid-19 mortality between 2020 and 2021.Thomas R Basala, Marissa E Dulas, Alexis Albers, Sara D Olson, Brynn Okeson, Jay H Traverse> ;American Heart Journal Plus. 2024 Jan 1
- Microvascular obstruction identifies a subgroup of patients who benefit from stem cell therapy following ST-elevation myocardial infarction.Sarah J Davidson, Jerome Roncalli, Daniel Surder, Roberto Corti, Atul R Chugh, Phillip C Yang, Timothy D Henry, Larissa Stanberry, Patricia Lemarchand, Jeau-Paul Bereg...> ;American Heart Journal. 2023 May 1
- 2 citationsFrequency and outcomes of STEMI patients presenting between 12 and 24 h after symptom onset: Late-presenting STEMI.Anna C Gonzalez Griffin, Mehmet Yildiz, Steven Bradley, Jenna E Smith, Santiago Garcia, Christian W Schmidt, Ross Garberich, Evan Walser-Kuntz, Jay Traverse, James G J...> ;Catheterization and Cardiovascular Interventions. 2023 Jan 1
- Join now to see all
Journal Articles
- Prevalence, Trends, and Outcomes of Higher Risk Percutaneous Coronary Interventions Among Patients Without Acute Coronary Syndromes☆☆☆Ivan Chavez, M Nicholas Burke, Daniel Lips, Jay Traverse, Emmanouil S Brilakis, Anil Poulose, Michael Mooney, Paul Sorajja, Yale Wang, ScienceDirect
- Meta‐Analysis of the Impact of Successful Chronic Total Occlusion Percutaneous Coronary Intervention on Left Ventricular Systolic Function and Reverse RemodelingIvan Chavez, Yale Wang, Emmanouil S Brilakis, Louis P Kohl, Daniel Lips, Michael Mooney, Paul Sorajja, Anil Poulose, M Nicholas Burke, Jay Traverse, Journal of Interventional Cardiology
Press Mentions
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial InfarctionMay 10th, 2022- Novel Hydrogel May Help Repair Cardiac TissueJuly 9th, 2020
FDA Stage 1 Trial Reveals Hydrogel to Repair Heart Is Safe to Inject in People– an InitiallySeptember 16th, 2019- Join now to see all
Grant Support
- Cardiovascular Cell Therapy Research Network (CCTRN)NHLBI2012–Present
- Phase II Clinical Trial of Postconditions in patients with ST- Elevation Myocardial InfarctionNHLBI2011–Present
Professional Memberships
- Fellow
- American Physiological SocietyMember
- Fellow
- Society for Coronary Angiography and InterventionsFellow
Hospital Affiliations
Abbott Northwestern HospitalMinneapolis, Minnesota
New Ulm Medical CenterNew Ulm, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
